Photo of C. Ola Landgren taken from news.med.miami.edu
Aug 2, 2024, 23:39
The efficacy of BMA and the role of precision medicine in Myeloma
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, shared a post by HealthTree Foundation on X, adding:
“Thank you HealthTree Foundation for the interview at EHA2024 on bispecific monoclonal antibodies in myeloma. Lots of exciting new data. Great for patients!”
Quoting HealthTree Foundation‘s post:
“MYELOMA: C. Ola Landgren, MD discusses the efficacy of bispecific antibodies and the role of precision medicine in managing this complex disease.”
Source: C. Ola Landgren/X and HealthTree Foundation/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14